Biology subjects

Boddey, J. A.

Publications and source records attributed to Boddey, J. A..

7 recordsLinked to original sources

bioRxiv2026

Temporal expression of liver-stage malaria antigens shapes vaccine efficacy

Vaccine-induced cytotoxic T cells can prevent malaria by killing parasite-infected hepatocytes during the liver stage. While several antigenic targets have been identified, little consideration has been given to their temporal expression. Here, we identified SERA1 of Plasmodium berghei as a late liver-stage target in rodent malaria and further showed that the classic vaccine antigen thrombospondin-related adhesion protein (TRAP) is only an early target. While vaccination with either antigen alone was modestly protective, combining these antigens enabled killing over the entire liver-stage, greatly improving efficacy. Given the relatively long liver-stage in human malaria, our findings imply TRAP-dependent vaccines likely utilize only a small proportion of the available liver-stage to eradicate parasites. Our findings further indicate that considerations of temporal coverage when selecting vaccine antigens will improve efficacy. One-Sentence SummaryTemporally defining presentation of liver-stage antigens informs rational combinations that maximize malaria vaccine efficacy.

immunology↗

bioRxiv2025

Cas9-expressing HC-04 hepatocytes facilitate CRISPR-based analysis of Plasmodium falciparum sporozoite-host interactions

Sporozoites of Plasmodium falciparum, the deadliest malaria parasite, are transmitted into the skin by infected mosquitoes and migrate to the liver to initiate infection. There, they invade hepatocytes and develop into exoerythrocytic merozoites that, eventually, enter the bloodstream and invade erythrocytes, leading to malaria. The parasite journey involves cell traversal, where sporozoites transiently enter and exit host cells beginning in the skin, lysing membranes to move deeper into tissue and evade immune cell destruction. After reaching the liver and traversing several hepatocytes, sporozoites productively invade a final hepatocyte to establish liver-stage infection. The molecular mechanisms underlying traversal, invasion, and intracellular development remain incompletely understood, particularly with respect to host determinants. To address this, we engineered human HC-04 hepatocytes, the only known cell line supporting P. falciparum liver-stage development, to express Cas9-mCherry, enabling CRISPR-based functional genomics studies. We validated Cas9 activity and demonstrated successful guide-RNA-directed gene disruption via non-homologous end joining in HC-04 Cas9+ (clone 2B3) cells. Optimized traversal and invasion assays with HC-04 2B3 cells led to a robust cytometric assay suitable for screening human genes involved in P. falciparum infection. As proof-of-concept, we performed a small screen involving disruption of 10 human genes previously implicated in infection by bacterial and viral pathogens, confirming utility of this platform. While no new host factors were identified for malaria parasites in this initial study, we have developed a tractable system for genome-wide CRISPR screens to uncover novel hepatocyte biology and host determinants of infection by liver-tropic pathogens.

microbiology↗

bioRxiv2025

Chemovaccination with a novel antimalarial targeting the late liver stage induces durable immunity against malaria

Vaccination with Plasmodium falciparum, the most lethal malaria parasite, using sporozoites that arrest during liver stage infection either by irradiation, genetic attenuation or chemotherapy have been developed, with late liver stage arrest providing very high efficacy. Such vaccines require complex manufacture, deployment and intravenous administration. Here, we report an alternative strategy of chemo-attenuation of malaria parasites at the late liver stage using first-in-class antimalarials under clinical development that target the parasite aspartyl proteases plasmepsin IX and X. A single low-dose infection with virulent Plasmodium berghei sporozoites followed by drug treatment cleared infection by producing chemo-attenuated liver merozoites (CALM) that induced sterile immunity in mice for up to 21 months. Protection arose from humoral responses to circumsporozoite protein and robust CD8+ T cell responses, including liver-resident memory cells reactive to diverse antigens including SERA1 and RPL6. Drug treatment also attenuated the human pathogen P. falciparum by preventing liver merozoites from infecting human erythrocytes in humanized chimeric liver mice, confirming that the mechanism of liver-stage merozoite attenuation (ie, CALM) via inhibition of plasmepsins IX and X is conserved, likely due to conservation of binding site amino acids of both proteases across the Plasmodium genus. Therefore, plasmepsin IX/X-targeting antimalarials offer a new approach to achieving late liver stage arrest against all circulating Plasmodium species and strains. This study establishes the basis for clinical trials assessing CALM for chemoprevention and chemovaccination against diverse Plasmodium species to advance new therapeutic strategies in malaria control. It also suggests the prospect of chemovaccination by natural exposure to mosquito-borne parasites if development of a long-acting injectable formulation of plasmepsin IX/X inhibitors proves feasible.

microbiology↗

bioRxiv2025

The vaccine candidate Liver Stage Antigen 3 is exported during Plasmodium falciparum infection and required for liver-stage development in humanized mice

Plasmodium falciparum remodels infected erythrocytes using exporting effector proteins. Parasites express the aspartyl protease plasmepsin V that processes proteins containing a PEXEL motif and the PTEX translocon to successfully export proteins. During liver-stage infection, PTEX is required for P. falciparum development, but which proteins are exported remain largely unclear, yet they may serve important functions and be presented by MHC-I molecules, thereby representing potential vaccine candidates. Here, we investigated liver stage antigen 3 (LSA3), an immunogenic protein of the Laverania subgenus of Plasmodium. We show that LSA3 possesses a PEXEL motif processed by plasmepsin V and is targeted to one or more membranes surrounding the blood-stage parasite, suggestive of the parasitophorous vacuole membrane (PVM). A subset of LSA3 also localizes in the erythrocyte, where it forms punctate structures that are not Maurers clefts but are soluble in biochemical fractionation assays reminiscent of J-dot proteins. During infection of human hepatocytes, antibodies to LSA3 co-localize with EXP1 and EXP2 at the PVM yet these antibodies were not detected beyond this membrane. Finally, genetic disruption of LSA3 in P. falciparum NF54 attenuated fitness at the liver stage, manifesting as a 40% reduction in parasite liver load by day 5 postinfection of humanized mice. The identification of LSA3 as a member of the P. falciparum exportome and important for liver-stage development confirms the hypothesized potential of exported proteins as promising vaccine candidates, underscoring the need for their continued discovery and biological characterization, including those expressed at the liver stage.

microbiology↗

bioRxiv2025

Host iron deficiency protects against Plasmodium infection and drives parasite molecular reprofiling.

Iron deficiency, anemia and Plasmodium infection represent significant global health challenges with overlapping geographical distributions, particularly affecting pregnant women in Africa, yet the mechanisms underlying their interactions remain poorly understood. We employed a multilayered approach combining clinical data from Malawian pregnant women (n=711) in the REVAMP trial, a genetic mouse model (Tmprss6-knockout), and in vitro P. falciparum cultures to clarify associations between iron status and malaria susceptibility. Iron deficiency was associated with 50% reduced P. falciparum parasitemia in pregnant women (95% CI [30%-64%], p<0.0001), while iron-deficient mice exhibited significantly improved survival against P. berghei (median 15.5 days vs. 7.0 days for WT mice) and protection from cerebral malaria (83% vs 17% survival). Iron chelation induced substantial transcriptomic and proteomic changes in cultured parasites, affecting host cell invasion and nutrient acquisition processes. Importantly, intravenous iron supplementation did not increase subsequent parasitemia when coupled with malaria prevention. These findings demonstrate that iron deficiency protects against Plasmodium infection and support WHO recommendations for iron supplementation in malaria-endemic regions when combined with adequate malaria prevention strategies.

cell biology↗

bioRxiv2023

Malaria parasite resistance to azithromycin is not readily transmitted by mosquitoes

Antimalarials are now used in combination with partner drugs to stem parasite drug resistance. Partners are often older, safe, cheap drugs, but resistance is already circulating for many, which raises the risk of selecting for multidrug resistance. If the partner drug(s) could be refractory to the spread of resistance, better resistance control could be implemented. We tested whether resistance to the antibiotic azithromycin, which kills malaria parasites by perturbing prokaryote-like protein synthesis in the apicoplast (relict plastid), had fitness costs to the spread of parasites via mosquitoes where parasites are not under drug pressure. Azithromycin resistance mutations in both rodent and human malaria parasites had a negative impact on the ability of resistant parasites to transmit from one vertebrate host to another via mosquitoes. Azithromycin resistance will therefore be less likely to spread geographically, making it an attractive option as a perennial partner compound to protect appropriate frontline antimalarials.

molecular biology↗

bioRxiv2018

Aspartyl Protease 5 matures virulence factors found at the host-parasite interface in Toxoplasma gondii

Toxoplasma gondii infects approximately 30% of the worlds population, causing disease primarily during pregnancy and in individuals with weakened immune systems. Toxoplasma secretes and exports effector proteins that modulate the host during infection and several of these proteins are processed by the Golgi-associated Aspartyl Protease 5 (ASP5). Here, we identify ASP5 substrates by selectively enriching N-terminally-derived peptides from wildtype and {Delta}asp5 parasites. We reveal over two thousand unique Toxoplasma N-terminal peptides, mapping to both natural N-termini and protease cleavage sites. Several of these peptides mapped directly downstream of the characterised ASP5-cleavage site, arginine-arginine-leucine (RRL). We validate candidates as true ASP5 substrates, revealing they are not processed in parasites lacking ASP5, nor in wild type parasites following mutation of the motif from RRL{longrightarrow}ARL. All new ASP5 substrates are dense granule proteins, and interestingly none appear to be exported, thus differing from the analogous system in related Plasmodium spp., instead revealing that the majority of substrates reside within the parasitophorous vacuole (PV), and its membrane (the PVM), including two kinases and one phosphatase. Furthermore, we show that several of these ASP5-substrates are virulence factors, with their removal leading to attenuation in a mouse model, suggesting that phosphorylation at the host-parasite interface is important for virulence. Collectively, these data constitute the first in-depth analyses of the total list of ASP5 substrates, and shed new light on the role of ASP5 as a maturase of dense granule proteins during the Toxoplasma lytic cycle.

microbiology↗